专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090286761A1 Anti-Proliferative and Anti-Inflammatory Agent Combination for Treatment of Vascular Disorders with an Implantable Medical Device 有权
标题翻译：用植入式医疗器械治疗血管疾病的抗增生和抗炎药物组合
公开(公告)号：US20090286761A1
公开(公告)日：2009-11-19
申请号：US12191209
申请日：2008-08-13
申请人： Jin Cheng , Stephen Dugan , Gordon Stewart , Gina Zhang , Nancy Kirsten , Paul Consigny , Christopher Feezor , Gene Park , Wouter Roorda , Syed F.A. Hossainy
发明人： Jin Cheng , Stephen Dugan , Gordon Stewart , Gina Zhang , Nancy Kirsten , Paul Consigny , Christopher Feezor , Gene Park , Wouter Roorda , Syed F.A. Hossainy
IPC分类号： A61K31/56 , A61P7/00
CPC分类号： A61L31/16 , A61F2/91 , A61F2250/0067 , A61F2250/0068 , A61K31/4745 , A61K31/56 , A61K31/573 , A61L31/10 , A61L31/148 , A61L2300/222 , A61L2300/416 , A61L2300/45 , A61K2300/00
摘要： A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 μg, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).
摘要翻译：提供了一种药物递送系统，其包括至少100杯依维莫司和氯倍他索，使得依维莫司与氯倍他索的比例至少为10：1（w / w），依维莫司的重量比为至少10倍氯倍他索该系统可以是支架。还提供了治疗血管的再狭窄或易损斑块的方法，所述方法包括向患者局部施用选自雷帕霉素（西罗莫司），Biolimus A9，deforolimus，AP23572，他克莫司，替西罗莫司，吡美莫司， 40-（2-羟基）乙基雷帕霉素（依维莫司），40-O-（3-羟基）丙基雷帕霉素，40-O- [2-（2-羟基）乙氧基]乙基雷帕霉素，40- O-四唑基雷帕霉素和40-表 - （N1-四唑基）雷帕霉素，并且对患者局部施用由氯倍他索组成的第二药物，其中局部施用的第一药物的最小量为100杯，其中第二种药物的第一种药物例如为10：1〜100：1（w / w）。

2. 发明申请

US20080124372A1 Morphology profiles for control of agent release rates from polymer matrices 审中-公开
标题翻译：用于控制聚合物基质的试剂释放速率的形态概况
公开(公告)号：US20080124372A1
公开(公告)日：2008-05-29
申请号：US11448956
申请日：2006-06-06
申请人： Syed F. A. Hossainy , Fuh-Wei Tang , Lothar Kleiner , Thierry Glauser , Yiwen Tang , Wouter Roorda , Stephen Pacetti , Gina Zhang , Yung-Ming Chen , Andrew F. McNiven , Sean A. McNiven , Brandon J. Yoe
发明人： Syed F. A. Hossainy , Fuh-Wei Tang , Lothar Kleiner , Thierry Glauser , Yiwen Tang , Wouter Roorda , Stephen Pacetti , Gina Zhang , Yung-Ming Chen , Andrew F. McNiven , Sean A. McNiven , Brandon J. Yoe
IPC分类号： A61F2/06 , B05D3/00 , A61K47/48 , A61K31/436 , A61K31/337 , A61K31/46 , A61P9/00
CPC分类号： A61L31/10 , A61L27/40 , A61L27/44 , A61L27/50 , A61L27/54 , A61L31/12 , A61L31/14 , A61L31/16 , A61L2300/00
摘要： The present disclosure teaches methods of controlling the release rate of agents from a polymeric matrix that include designing and creating a predetermined initial morphology (IM) profile in a polymeric matrix. The teachings indicate, inter alia, that control over the release rate of agents can provide for an improved control over the administration of agents as well as have an effect upon the mechanical integrity and absorption rate of the polymeric matrix.
摘要翻译：本公开教导了控制来自聚合物基质的试剂的释放速率的方法，其包括在聚合物基质中设计和产生预定的初始形态（IM）分布。教导尤其表明，对药剂释放速率的控制可以提供对药剂施用的改进控制，以及对聚合物基质的机械完整性和吸收速率的影响。

3. 发明申请

US20050106203A1 Polyacrylates coating for implantable medical devices 有权
标题翻译：用于可植入医疗器械的聚丙烯酸酯涂层
公开(公告)号：US20050106203A1
公开(公告)日：2005-05-19
申请号：US10176504
申请日：2002-06-21
申请人： Wouter Roorda , Ni Ding , Stephen Pacetti , Eugene Michal , Ashok Shah , Syed Hossainy
发明人： Wouter Roorda , Ni Ding , Stephen Pacetti , Eugene Michal , Ashok Shah , Syed Hossainy
IPC分类号： A61L31/00 , A61F2/84 , A61K31/436 , A61L27/34 , A61L31/10 , A61L31/16 , A61K47/32
CPC分类号： A61L31/16 , A61L31/10 , A61L2300/416 , A61L2300/602 , A61L2300/606 , A61L2300/608 , A61L2420/08 , C08L33/10 , C08L33/06
摘要： A coating for a medical device, particularly for a drug eluting stent, is described. The coating can include a polyacrylate, a blend of polyacrylates, or a blend of the polyacrylate with other polymers, for example, poly(ethylene-co-vinyl alcohol).
摘要翻译：描述了用于医疗装置的涂层，特别是用于药物洗脱支架的涂层。涂层可以包括聚丙烯酸酯，聚丙烯酸酯的共混物或聚丙烯酸酯与其它聚合物的共混物，例如聚（乙烯 - 共 - 乙烯醇）。

4. 发明授权

US09248121B2 Medical devices for controlled drug release 有权
标题翻译：用于控释药物的医疗器械
公开(公告)号：US09248121B2
公开(公告)日：2016-02-02
申请号：US11839093
申请日：2007-08-15
申请人： Wouter Roorda
发明人： Wouter Roorda
IPC分类号： A61K31/436 , A61K9/00 , A61L31/14 , A61L31/16
CPC分类号： A61K31/436 , A61F2250/0067 , A61F2250/0068 , A61L31/10 , A61L31/146 , A61L31/16 , A61L2300/608 , B22F3/008 , B22F3/105 , B22F2003/1051 , B22F2003/1054
摘要： The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores of the porous body in a manner that protects the matrix from mechanical damage. The medical device may therefore be used for controlled drug release applications. Additionally, the present invention discloses a method for using the medical device for the treatment and prevention of diseases in mammals. This invention further relates to a method for using the medical device for treating and preventing vascular diseases.
摘要翻译：本发明是用于控制活性剂释放的医疗装置。医疗器具具有设置在其中的多孔体的支撑结构。含有有效量的至少一种活性剂的至少一种洗脱速率控制基质以保护基质免受机械损伤的方式设置在多孔体的孔内。因此，医疗装置可以用于受控药物释放应用。另外，本发明公开了一种使用该医疗装置来治疗和预防哺乳动物疾病的方法。本发明还涉及一种用于治疗和预防血管疾病的医疗装置的方法。

5. 发明授权

US08435550B2 Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device 有权
标题翻译：抗增殖和抗炎剂组合用于用植入式医疗装置治疗血管疾病
公开(公告)号：US08435550B2
公开(公告)日：2013-05-07
申请号：US12191209
申请日：2008-08-13
申请人： Jin Cheng , Stephen Dugan , Gordon Stewart , Gina Zhang , Nancy Kirsten , Paul Consigny , Christopher Feezor , Gene Park , Wouter Roorda , Syed F. A. Hossainy
发明人： Jin Cheng , Stephen Dugan , Gordon Stewart , Gina Zhang , Nancy Kirsten , Paul Consigny , Christopher Feezor , Gene Park , Wouter Roorda , Syed F. A. Hossainy
IPC分类号： A61F2/02
CPC分类号： A61L31/16 , A61F2/91 , A61F2250/0067 , A61F2250/0068 , A61K31/4745 , A61K31/56 , A61K31/573 , A61L31/10 , A61L31/148 , A61L2300/222 , A61L2300/416 , A61L2300/45 , A61K2300/00
摘要： A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 μg, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).
摘要翻译：提供了一种药物递送系统，其包括至少100杯依维莫司和氯倍他索，使得依维莫司与氯倍他索的比例至少为10：1（w / w），依维莫司的重量比为至少10倍氯倍他索该系统可以是支架。还提供了治疗血管的再狭窄或易损斑块的方法，所述方法包括向患者局部施用选自雷帕霉素（西罗莫司），Biolimus A9，deforolimus，AP23572，他克莫司，替西罗莫司，吡美莫司， 40-（2-羟基）乙基雷帕霉素（依维莫司），40-O-（3-羟基）丙基雷帕霉素，40-O- [2-（2-羟基）乙氧基]乙基雷帕霉素，40- O-四唑基雷帕霉素和40-表 - （N1-四唑基）雷帕霉素，并且对患者局部施用由氯倍他索组成的第二药物，其中局部施用的第一药物的最小量为100杯，其中第二种药物的第一种药物例如为10：1〜100：1（w / w）。

6. 发明授权

US08277436B2 Vessel enlargement by arteriogenic factor delivery 有权
标题翻译：血管扩张由动脉血因子递送
公开(公告)号：US08277436B2
公开(公告)日：2012-10-02
申请号：US12057882
申请日：2008-03-28
申请人： Wouter Roorda
发明人： Wouter Roorda
IPC分类号： A61K38/00 , C07K14/52 , C07K14/515
CPC分类号： A61M25/104 , A61K31/198 , A61K31/223 , A61K31/417 , A61K31/557 , A61K38/043 , A61K38/1725 , A61K38/1774 , A61K38/1777 , A61K38/178 , A61K38/1825 , A61K38/19 , A61M25/0084 , A61M2025/0086 , A61M2025/0087 , A61M2025/105
摘要： A method of delivering an arteriogenic factor. The factor is delivered in a medically effective manner to structurally enlarge blood vessel. A distal portion of a catheter can be advanced to an existing blood vessel to deliver the arteriogenic factor.
摘要翻译：递送动脉生成因子的方法。该因素以医学上有效的方式进行结构扩大血管。导管的远端部分可以前进到现有血管以递送动脉生成因子。

7. 发明申请

US20080319475A1 Methods, Devices, and Apparatus for Managing Access Through Tissue 有权
标题翻译：用于管理通过组织进入的方法，装置和装置
公开(公告)号：US20080319475A1
公开(公告)日：2008-12-25
申请号：US11767818
申请日：2007-06-25
申请人： Ian J. Clark , Wouter Roorda
发明人： Ian J. Clark , Wouter Roorda
IPC分类号： A61B17/08
CPC分类号： A61B17/0057 , A61B17/083 , A61B17/10 , A61B2017/00637 , A61B2017/00668
摘要： Devices and methods for managing access through tissue is disclosed. The device includes a body. The body is movable from a pre-deployed configuration towards a deployed configuration. The device includes a plurality of tissue engaging portions that extend from the body. At least a portion of the tissue engaging portions are obtuse. At least two of the tissue engaging portions are separated by a first distance in the deployed configuration and a second distance in the pre-deployed configuration. The first distance is smaller than the second distance. The method includes deploying a closure element to tissue adjacent a tissue opening to substantially close the opening following a first procedure. The method also includes selectively opening the opening in the tissue by advancing a distal end of a medical device through the deployed closure element as a part of or before a second procedure.
摘要翻译：公开了用于管理通过组织进入的装置和方法。该装置包括一个主体。身体可以从预部署配置朝向部署配置移动。该装置包括从身体延伸的多个组织接合部分。组织接合部分的至少一部分是钝的。组织接合部分中的至少两个在展开配置中分开第一距离，并且在预部署配置中分开第二距离。第一距离小于第二距离。该方法包括将封闭元件部署到邻近组织开口的组织，以在第一程序之后基本上关闭开口。该方法还包括通过使医疗装置的远端作为第二程序的一部分或之前通过展开的闭合元件前进而选择性地打开组织中的开口。

8. 发明申请

US20060198897A1 Polycationic peptide coatings and methods of coating implantable medical devices 有权
公开(公告)号：US20060198897A1
公开(公告)日：2006-09-07
申请号：US11213288
申请日：2005-08-26
申请人： Stephen Pacetti , Eugene Michal , Syed Hossainy , Ni Ding , Wouter Roorda
发明人： Stephen Pacetti , Eugene Michal , Syed Hossainy , Ni Ding , Wouter Roorda
IPC分类号： A61K9/50 , A61K9/16
CPC分类号： A61K31/727 , A61K31/728 , A61K31/737 , A61L31/10 , C08L89/00
摘要： Coatings for medical devices which include polycationic peptides such as L-arginine and methods for fabricating the coatings are disclosed.

9. 发明申请

US20060018944A1 Polycationic peptide coatings and methods of coating implantable medical devices 有权
公开(公告)号：US20060018944A1
公开(公告)日：2006-01-26
申请号：US11213290
申请日：2005-08-26
申请人： Stephen Pacetti , Eugene Michal , Syed Hossainy , Ni Ding , Wouter Roorda
发明人： Stephen Pacetti , Eugene Michal , Syed Hossainy , Ni Ding , Wouter Roorda
IPC分类号： A61K31/727 , A61F13/00
CPC分类号： A61K31/727 , A61K31/728 , A61K31/737 , A61L31/10 , C08L89/00
摘要： Coatings for medical devices which include polycationic peptides such as L-arginine and methods for fabricating the coatings are disclosed.

10. 发明申请

US20060002968A1 Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders 审中-公开
公开(公告)号：US20060002968A1
公开(公告)日：2006-01-05
申请号：US10882506
申请日：2004-06-30
申请人： Gordon Stewart , Gina Zhang , Nancy Kristen , Paul Consigny , Stephen Dugan , Gene Park , Christopher Feezor , Wouter Roorda , Syed Hossainy
发明人： Gordon Stewart , Gina Zhang , Nancy Kristen , Paul Consigny , Stephen Dugan , Gene Park , Christopher Feezor , Wouter Roorda , Syed Hossainy
IPC分类号： A61K31/4745 , A61F2/00
CPC分类号： A61K31/4745 , A61F2250/0067 , A61K31/436 , A61K31/573 , A61L31/10 , A61L31/16 , A61L2300/41 , A61L2300/416 , A61L2300/45 , A61K2300/00
摘要： Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式